Sugi Predict

Sugi Predict / Compounds / SCHEMBL2706148

SCHEMBL2706148

SCHEMBL2706148

CC(C)/C=C/c1ccc(NC(=O)C(C)C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.58
▸ KMT2A Q03164 5/20 0.58
▸ MAPT P10636 5/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ KDM4E B2RXH2 3/20 0.58
▸ HPGD P15428 2/20 0.58
▸ GAA P10253 1/20 0.58
▸ RXFP1 Q9HBX9 1/20 0.53
▸ NPSR1 Q6W5P4 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ RAB9A P51151 2/20 0.50
▸ HTT P42858 1/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA1 P00915 1/20 0.50
▸ CA2 P00918 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ MLYCD O95822 1/20 0.49
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14358741 0.89 ALDH1A1 (0.60) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL14358738 0.89 ALDH1A1 (0.60) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL18462514 0.84 KMT2A (0.54) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL18880072 0.81 ALDH1A1 (0.73) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL2832203 0.80 ALDH1A1 (0.58) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL14462220 0.80 ALDH1A1 (0.56) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL13139478 0.79 PTPN1 (0.63) ALDH1A1KMT2AMAPTKDM4EHPGD
SCHEMBL14358477 0.79 MMP13 (0.59) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL14358480 0.79 MMP13 (0.59) ALDH1A1KMT2AMAPTMEN1KDM4E
SCHEMBL11338210 0.78 CA1 (0.53) ALDH1A1KMT2AMAPTMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11738013-B2 Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors GILEAD SCIENCES, INC. (US) 2023-08-29 — — US disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 — — US disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 — — US disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 — — US disclosed
US-20170029408-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2017-02-02 — — US disclosed
US-9511056-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2016-12-06 — — US disclosed
US-8841278-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2014-09-23 — — US disclosed
US-20140249074-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2014-09-04 — — US disclosed
US-8822430-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2014-09-02 — — US disclosed
US-8669234-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2014-03-11 — — US disclosed
US-20140051656-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-20 — — US disclosed
US-20140039021-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2014-02-06 — — US disclosed
US-8575118-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-11-05 — — US disclosed
US-20130137877-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-05-30 — — US disclosed
US-20120264711-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-10-18 — — US disclosed
US-8273341-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-09-25 — — US disclosed
US-20120157404-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-06-21 — — US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 — — US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051656-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885
US-20170029408-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885
US-20130137877-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885
US-20120264711-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885
US-20120157404-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885
US-11738013-B2 Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors HAVCR2, EIF2AK2, HSP90B1 ALDH1A1 3064/4885KMT2A 2756/4885MAPT 3191/4885
US-20140039021-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885
US-20140249074-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ALDH1A1 3957/4885KMT2A 3803/4885MAPT 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.